Skip to Content

Arzerra Approval History

Arzerra (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.

Development History and FDA Approval Process for Arzerra

Aug 31, 2016Approval Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
Jan 19, 2016Approval Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL
Oct 26, 2009Approval FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia
Jun 16, 2009FDA Extends Review of Arzerra (ofatumumab)
May 29, 2009GSK/Genmab Receive Favorable Recommendation for Arzerra from FDA Advisory Panel
May  4, 2009FDA Advisory Committee to Review Arzerra (Ofatumumab)
Apr  3, 2009Arzerra (Ofatumumab) Granted Priority Review By FDA
Jan 30, 2009GlaxoSmithKline and Genmab Submit Arzerra (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.